ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACAD ACADIA Pharmaceuticals

Not Yet Opened 10-28 16:00:00 EDT

20.32

+0.15

+0.74%

盘后20.24

-0.08-0.39%

19:30 EDT

High20.35	Low20.00	Vol1.34M
Open20.00	D1 Closing20.17	Amplitude1.74%
Mkt Cap3.50B	Tradable Cap2.62B	Total Shares172.31M
T/O27.06M	T/O Rate1.04%	Tradable Shares128.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACAD","market":"US","secType":"STK","nameCN":"ACADIA Pharmaceuticals","latestPrice":20.32,"timestamp":1793217600000,"preClose":20.17,"halted":0,"volume":1336007,"hourTrading":{"tag":"盘后","latestPrice":20.24,"preClose":20.32,"latestTime":"19:30 EDT","volume":57874,"amount":1175681.552356,"timestamp":1793230200949,"change":-0.08,"changeRate":-0.003937,"amplitude":0.004389},"delay":0,"changeRate":0.007436787307882923,"floatShares":128722546,"shares":172305518,"eps":2.195511,"marketStatus":"Not Yet Opened","change":0.15,"latestTime":"10-28 16:00:00 EDT","open":20,"high":20.35,"low":20,"amount":27062808.427409,"amplitude":0.017353,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.195511,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793260800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":20.17,"preHourTrading":{"tag":"盘前","latestPrice":20.17,"preClose":20.17,"latestTime":"08:23 EDT","volume":3278,"amount":65983.28814,"timestamp":1793190203663,"change":0,"changeRate":0,"amplitude":0.016857},"postHourTrading":{"tag":"盘后","latestPrice":20.24,"preClose":20.32,"latestTime":"19:30 EDT","volume":57874,"amount":1175681.552356,"timestamp":1793230200949,"change":-0.08,"changeRate":-0.003937,"amplitude":0.004389},"volumeRatio":1.065873,"impliedVol":0.5148,"impliedVolPercentile":0.741},"requestUrl":"/m/hq/s/ACAD","defaultTab":"news","newsList":[{"id":"1182983483","title":"Earning Preview: ACADIA Pharmaceuticals this quarter’s revenue is expected to increase by 20.26%, and institutional views are mostly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1182983483","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1182983483?lang=en_us&edition=fundamental","pubTime":"2026-10-28 22:17","pubTimestamp":1793197036,"startTime":"0","endTime":"0","summary":"Abstract ACADIA Pharmaceuticals will report quarterly results on November 4, 2026 Post-Mkt; investors will focus on revenue growth, margin durability, and EPS execution as consensus points to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: ACADIA Pharmaceuticals this quarter’s revenue is expected to increase by 20.26%, and institutional views are mostly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679416438","title":"Acadia Pharmaceuticals Participates in UBS Global Biopharma Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2679416438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679416438?lang=en_us&edition=fundamental","pubTime":"2026-10-29 04:05","pubTimestamp":1793217946,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals Participates in UBS Global Biopharma Conference Fireside ChatAcadia Pharmaceuticals will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Nov. 17, 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nNDL4q0NHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU2065171402.SGD","LU2065170008.USD","LU2065171311.SGD","BK4139","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677697791","title":"Acadia Pharmaceuticals R&D Head Elizabeth Thompson Retires Effective Oct. 23","url":"https://stock-news.laohu8.com/highlight/detail?id=2677697791","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677697791?lang=en_us&edition=fundamental","pubTime":"2026-10-24 04:52","pubTimestamp":1792788755,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals R&D Head Elizabeth Thompson Retires Effective Oct. 23ACADIA Pharmaceuticals executive vice president Elizabeth H.Z. Thompson retires as research and development head October 23,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nNDLnztdd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","LU2065169927.USD","LU2065171402.SGD","LU2065170008.USD","BK4139","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677604430","title":"Acadia Pharmaceuticals Sets Third-Quarter 2026 Results Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2677604430","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677604430?lang=en_us&edition=fundamental","pubTime":"2026-10-22 04:06","pubTimestamp":1792613161,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals Sets Third-Quarter 2026 Results AnnouncementAcadia Pharmaceuticals will report third-quarter 2026 financial results on Nov. 4, 2026, following the U.S. market close.Management w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDL2S7ZTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","LU2065169927.USD","LU2065171402.SGD","LU2065170008.USD","BK4139","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676499572","title":"Did Acadia Pharmaceuticals' Fall Catch You Out? What Investors Missed","url":"https://stock-news.laohu8.com/highlight/detail?id=2676499572","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676499572?lang=en_us&edition=fundamental","pubTime":"2026-10-19 09:43","pubTimestamp":1792374215,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals has had an attention grabbing year, from European approval of DAYBU for Rett syndrome to mixed Phase 2 data on remlifanserin that sparked legal investigations and analyst downgrades. Investors who held Acadia Pharmaceuticals from the start of the year are down 27.3%, including dividends. If you had been weighing a fresh position on 1 January 2026, how should these cross currents between DAYBU’s expansion and RADIANT’s stumble shape what you focus on next?\nNarratives are...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/did-acadia-pharmaceuticals-fall-catch-you-out-what-investors","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/did-acadia-pharmaceuticals-fall-catch-you-out-what-investors","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065171311.SGD","ACAD","ISBC","BK4139","LU2065171402.SGD","LU2065170008.USD","AKR","BK4080","BK4231","LU2065169927.USD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675532169","title":"Did Raised Revenue Guidance Just Shift Acadia Pharmaceuticals (ACAD) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2675532169","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675532169?lang=en_us&edition=fundamental","pubTime":"2026-10-16 02:32","pubTimestamp":1792089167,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals lifted its 2026 revenue guidance after strong Q2 performance and prescription trends for Nuplazid and Daybue, while Daybue also secured European Commission approval for treating neurobehavioral symptoms of Rett syndrome in patients aged five and older.\nDaybue’s new European authorization gives Acadia Pharmaceuticals a fresh route to expand its Rett syndrome franchise beyond the U.S. This development could change how investors think about the durability and reach of its...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/did-raised-revenue-guidance-just-shift-acadia-pharmaceutical","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/did-raised-revenue-guidance-just-shift-acadia-pharmaceutical","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675736172","title":"ACADIA Pharmaceuticals Shares Fall After UBS Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2675736172","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675736172?lang=en_us&edition=fundamental","pubTime":"2026-10-14 02:55","pubTimestamp":1791917704,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals  shares were down more than 4% in Tuesday trading after UBS downgraded the stock to neutral from buy, with a price target of $23.Trading volume stood at more than 1.1 million shares, compared with a daily average of about 1.8 million.Price: 18.55, Change: -0.86, Percent Change: -4.46","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675369038","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2675369038","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675369038?lang=en_us&edition=fundamental","pubTime":"2026-10-14 02:01","pubTimestamp":1791914489,"startTime":"0","endTime":"0","summary":"UBS downgraded Acadia Pharmaceuticals'  shares one notch to neutral and set a $23 price target.Acadia shares fell 4.7% amid intraday trading volume of over 903,000, versus a daily average of about 1.8 million.Applied Materials  said Monday it opened its new $5 billion semiconductor research and development center at its Sunnyvale, California, campus to accelerate the development and commercialization of chipmaking technologies for AI.The company expects revenue to double over the next few years without a proportional increase in its workforce as it expands its use of artificial intelligence, Bloomberg reported Monday.Shares slumped 8%, with intraday trading volume climbing to over 6.2 million, versus a daily average of about 6.8 million.Syndax Pharmaceuticals  said Monday its phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint of annualized forced vital capacity decline, and the company does not plan further development for the indication.Sh","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2065171402.SGD","LU0354030438.USD","LU1868837136.USD","LU0276348264.USD","RDVY","LU2931357623.SGD","LU2065170008.USD","SG9999002232.USD","APMI","BK4518","SHOC","SMH","CHPS","EPAI","LU1815336760.USD","LU1267930813.SGD","LU0096364046.USD","TINY","LU2023250843.SGD","LU0661504455.SGD","LU0127658192.USD","QQQG","RDVI","LU2089985449.USD","LU0061474960.USD","LU1046421795.USD","LU1868836591.USD","SNDX","BK4139","LU2106854487.HKD","LU1721428933.USD","WUGI","PSI","AMAU","LU0738911758.USD","SOXQ","BK4147","XNTK","LU1153585028.USD","LU1674673428.USD","LU2543165471.USD","ACAD","IE00BQXX3C00.GBP","LU0889565833.HKD","AMAT","LU0097036916.USD","LU1974910355.USD","AMA","TDV","LU0158827781.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675356126","title":"UBS Downgrades ACADIA Pharmaceuticals to Neutral From Buy, $23 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2675356126","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675356126?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:19","pubTimestamp":1791890389,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $31.95, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675801030","title":"Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675801030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675801030?lang=en_us&edition=fundamental","pubTime":"2026-10-13 01:10","pubTimestamp":1791825017,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pfizer-pfe-acadia-pharmaceuticals-acad-and-insmed-insm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pfizer-pfe-acadia-pharmaceuticals-acad-and-insmed-insm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1023059063.AUD","LU0122379950.USD","BK4581","LU1066053197.SGD","OZEM","SG9999001176.SGD","LU0306806265.USD","LU0225284248.USD","SG9999011175.SGD","LU0889565916.HKD","BK4534","SG9999001176.USD","LU2065171311.SGD","SG9999002224.SGD","LU0170899867.USD","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0985481810.HKD","SGXZ57979304.SGD","LU0109394709.USD","SG9999002232.USD","LU1057294990.SGD","IE00BBT3K403.USD","LU2065170008.USD","BK4588","BK4007","LU0225771236.USD","LU0456855351.SGD","LU0058720904.USD","BK4550","IE00B19Z3B42.SGD","LU0289739699.SGD","ACAD","BK4533","LU1066051498.USD","LU2596442595.SGD","SG9999013999.USD","BK4568","LU0053671581.USD","LU0320765992.SGD","LU1883839398.USD","IE0002270589.USD","LU0306807586.USD","BK4139","SG9999003800.SGD","LU0234572021.USD","LU0321505868.SGD","BK4599","LU2065169927.USD","BK4585","BK4592","INSM","PFE","IE00B3T34201.USD","LU1894683348.USD","LU2065171402.SGD","IE00BLSP4239.USD","IE000M9KFDE8.USD","LU0321505439.SGD","LU1894683264.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673207994","title":"RBC Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2673207994","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673207994?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:03","pubTimestamp":1791457418,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $31.95, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673073702","title":"Acadia Pharmaceuticals Inc. : RBC Cuts Target Price to $36 from $37","url":"https://stock-news.laohu8.com/highlight/detail?id=2673073702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673073702?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:02","pubTimestamp":1791453723,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U0WQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACAD","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","BK4139","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673034134","title":"Acadia Pharmaceuticals (ACAD) After Patent And RADIANT Updates Is The Undervalued View Too Simple","url":"https://stock-news.laohu8.com/highlight/detail?id=2673034134","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673034134?lang=en_us&edition=fundamental","pubTime":"2026-10-06 15:14","pubTimestamp":1791270858,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals (ACAD) just picked up two important pipeline milestones. Fresh US patent protection for Rett therapy trofinetide and Phase 2 RADIANT data for remlifanserin are now in focus for anyone tracking the stock.\nDespite this twin pipeline update, Acadia Pharmaceuticals’ share price has fallen about 28% over the past month and about 23% year to date, while the 1-year total shareholder return is down roughly 7%. This suggests that recent news is being weighed against longer term...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/acadia-pharmaceuticals-acad-after-patent-and-radiant-updates","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/acadia-pharmaceuticals-acad-after-patent-and-radiant-updates","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065171402.SGD","LU2065171311.SGD","ACAD","LU2065169927.USD","LU2065170008.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673086090","title":"Acadia looks to have settled case with Zydus, says RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673086090","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673086090?lang=en_us&edition=fundamental","pubTime":"2026-10-06 01:35","pubTimestamp":1791221721,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams says the firm’s checks found that Acadia Pharmaceuticals (ACAD) and generic drugmaker Zydus filed a joint stipul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acadia-looks-to-have-settled-case-with-zydus-says-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acadia-looks-to-have-settled-case-with-zydus-says-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKR","GSIB","BK4139","LU0310800379.SGD","LU0708994859.HKD","BK4231","LU0029864427.USD","ACAD","LU2065169927.USD","BK4207","BK4080","LU1267930573.SGD","LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671301268","title":"Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2671301268","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671301268?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:17","pubTimestamp":1790630276,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals  said late Monday the US Patent and Trademark Office issued a notice of allowance for a patent application covering weight-banded dosing of trofinetide for the treatment of Rett syndrome.The company said the patent, if issued, is expected to provide US protection for trofinetide through March 28, 2041, including six months of pediatric exclusivity, extending protection by nearly five years.Trofinetide is marketed in the US as \"Daybue\" and \"Daybue Stix\" for the treatment of Rett syndrome in adults and children age 2 and older. The drug is also covered by a method-of-use patent that expires in July 2036, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD","LU2065171402.SGD","USRD","LU2065171311.SGD","LU2065169927.USD","BK4231","LU2065170008.USD","AKR","BK4080","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671683972","title":"Helix BioPharma Names Karen Krumeich Board Chair, Adds Three Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2671683972","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671683972?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:15","pubTimestamp":1790630131,"startTime":"0","endTime":"0","summary":"Helix BioPharma names Karen Krumeich board chair, adds three directorsHelix BioPharma appointed Karen Krumeich, Jamieson Bondarenko, Charmaine Lykins, Dirk Brockstedt to its board, effective Sept. 28,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL9JqR7K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK5011","LU1487256676.USD","LU2065169927.USD","IE0002141913.USD","LU0971552673.USD","LU1400636574.HKD","LU0161305163.EUR","BK4588","LU1032466523.USD","LU1645745479.HKD","FTXH","LU2065171311.SGD","LU2125154778.USD","BK4139","LU2596442595.SGD","LU2065171402.SGD","LU0306807586.USD","LU1868836591.USD","LU0058720904.USD","LU0985481810.HKD","GSK.UK","IE00BJJMRZ35.SGD","LU1430594728.SGD","LU1236620750.USD","IE00B3T34201.USD","LU2125154935.USD","LU1074936037.SGD","LU2646069778.SGD","IE0034235071.USD","LU1989771016.USD","IE00BWDBJ516.SGD","IE00BFTCPJ56.SGD","LU1868836914.USD","LU2468319806.SGD","IE00B2B36J28.USD","LU1309081286.SGD","LU0306806265.USD","LU0203345920.USD","BK4581","LU0114720955.EUR","LU1400636657.SGD","IHE","IE00BSNM7G36.USD","BMY","BK4007","LU0109981661.USD","LU0575583348.USD","LU2133065610.SGD","SG9999001176.SGD","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671257465","title":"Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, Extending U.S. Patent Protections to March 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2671257465","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671257465?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625936,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45K0GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","BK4139","ACAD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670607429","title":"Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670607429","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670607429?lang=en_us&edition=fundamental","pubTime":"2026-09-26 01:42","pubTimestamp":1790358164,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics  may benefit from continued momentum for its depression and Alzheimer's agitation treatment Auvelity, with prescription data showing solid weekly growth, Mizuho said Friday in a report.Data from Bloomberg Symphony and IQVIA indicated double-digit percentage increases in total and new prescriptions, suggesting Auvelity's launch in Alzheimer's agitation is off to an encouraging start, the report said.The positive trends emerge as competitor Acadia Pharmaceuticals  reported weaker phase 2 results in Alzheimer's-related psychosis, which may help Axsome's positioning in the Alzheimer's and depression treatment markets, Mizuho said.Mizuho maintained its outperform rating on Axsome with a $316 price target.Price: 196.49, Change: +0.46, Percent Change: +0.23","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD","LU2065171402.SGD","LU2065171311.SGD","LU2065169927.USD","LU2065170008.USD","AXSM","BK4505","PTH","BK4139","BK4585","BK4007","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670542610","title":"Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670542610","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670542610?lang=en_us&edition=fundamental","pubTime":"2026-09-26 00:34","pubTimestamp":1790354048,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals'  favorable risk-reward remains intact despite remlifanserin narrowly missing statistical significance in a phase 2 trial in Alzheimer's disease psychosis, with the commercial base business supporting valuation, Deutsche Bank said in a Friday note.The 60 milligram dose narrowly missed statistical significance, but Deutsche Bank said the data showed a dose response, separation from placebo beginning at Week 2 and widening through Week 6, and a clean safety profile.The bank said remlifanserin has a pimavanserin-like profile that could be attractive commercially, supported by long-dated intellectual property.Deutsche Bank also cited improving commercial prospects for Nuplazid and Daybue.The investment bank reduced its probability of success for remlifanserin in Alzheimer's disease psychosis and Lewy body dementia psychosis.Deutsche Bank maintained its Buy rating and lowered its price target to $31 from $38.Shares of Acadia were 5.7% lower in Friday afternoon trading","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK4588","LU2065170008.USD","BK4139","ACAD","BK4552","DB","LU2065171311.SGD","BK4566","BK4231","LU2065169927.USD","BK4118","LU2065171402.SGD","AKR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670442447","title":"Deutsche Bank Lowers Price Target on ACADIA Pharmaceuticals to $31 From $38, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2670442447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670442447?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:30","pubTimestamp":1790335828,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $32.37, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD","DB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acadia.com","stockEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0102},{"period":"3month","weight":-0.2347},{"period":"6month","weight":-0.0743},{"period":"1year","weight":-0.1017},{"period":"ytd","weight":-0.2392}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.1241},{"period":"ytd","weight":0.1326}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.058102},{"month":2,"riseRate":0.636364,"avgChangeRate":0.023325},{"month":3,"riseRate":0.409091,"avgChangeRate":0.049753},{"month":4,"riseRate":0.454545,"avgChangeRate":0.00093},{"month":5,"riseRate":0.545455,"avgChangeRate":0.056897},{"month":6,"riseRate":0.521739,"avgChangeRate":-0.007217},{"month":7,"riseRate":0.608696,"avgChangeRate":0.051329},{"month":8,"riseRate":0.565217,"avgChangeRate":0.019184},{"month":9,"riseRate":0.478261,"avgChangeRate":0.009767},{"month":10,"riseRate":0.478261,"avgChangeRate":-0.023725},{"month":11,"riseRate":0.454545,"avgChangeRate":0.031974},{"month":12,"riseRate":0.545455,"avgChangeRate":0.059204}],"exchange":"NASDAQ","name":"ACADIA Pharmaceuticals","nameEN":"ACADIA Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACADIA Pharmaceuticals(ACAD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACADIA Pharmaceuticals,ACAD,ACADIA Pharmaceuticals股票,ACADIA Pharmaceuticals股票老虎,ACADIA Pharmaceuticals股票老虎国际,ACADIA Pharmaceuticals行情,ACADIA Pharmaceuticals股票行情,ACADIA Pharmaceuticals股价,ACADIA Pharmaceuticals股市,ACADIA Pharmaceuticals股票价格,ACADIA Pharmaceuticals股票交易,ACADIA Pharmaceuticals股票购买,ACADIA Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACADIA Pharmaceuticals(ACAD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}